Karachi: GlaxoSmithKline Pakistan Limited has announced the resignation of its Chief Financial Officer and Executive Director, Mr. Hasham Baber, who will be transitioning to a new role within the GSK Group. Mr. Baber is set to assume the position of Senior Finance Director at GSK Saudi Arabia, effective June 30, 2026, marking the end of his tenure at GlaxoSmithKline Pakistan.

The company, in its official communication, confirmed the departure of Mr. Baber, highlighting his noteworthy contributions to the organization. The transition is part of a broader career advancement within the GSK Group, underscoring the internal mobility and career development opportunities available within the multinational corporation.

According to information available from the Pakistan Stock Exchange (PSX), GlaxoSmithKline Pakistan Limited has yet to announce Mr. Baber's successor. The company assured stakeholders that further appointments regarding the Chief Financial Officer and Board membership will be communicated to the Pakistan Stock Exchange in due course.

The announcement has been made available to the TRE Certificate Holders of the Exchange. GlaxoSmithKline Pakistan operates within the designated market category of the pharmaceutical industry, a sector known for its dynamic and essential nature in the global economy.